nextpoint therapeutics

10-01-2023 Print. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. 13353 Berlin 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Our innovative approach integrates foundational. Copyright and Legal Notice. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. ProBioGen Executes a Master Service Agreement with NextPoint Global, Bayer To exercise your rights, you may contact us as at. Statements, Reports The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Dr. Zang is professor of microbiology & immunology, of medicine, . Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. announcements and other documents available in electronic format on this webpage does not constitute implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. The securities are only available to, and any invitation, However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. 1 Wei Y, Ren X, Galbo PM Jr, et al. Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). New Talent, Bayer 04 Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. focus on the areas of health care and nutrition. (DE), Bayer The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. The following materials are not directed at or to be accessed by persons located in the United Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. Experience with Ph 1-3 immuno-oncology clinical trials preferred. I understand that it may affect my rights. Bayer, Meet on 40789 Monheim am Rhein This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Publications, Job us, Talent For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Fakes, Background Arabia, South Phone: NextPoint Therapeutics Announces $80 Million Series B Financing co-led the world. or the solicitation of an offer to buy or subscribe for, any securities. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Republic, Ireland, Republic Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. us, How Natural Scientists, Global Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical offered or sold 2021 Feb;9(2):156-169. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. Deforestation and Forest Degradation, Postion indirectly, in or into the United States by use of the mails or by any means or instrumentality NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. who wishes to view these materials must first satisfy themselves that they are not subject to any Positions, Protection Responsible Care, Bayer We do not knowingly collect information from minors under the age of 13 years without parental consent. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. There will be no public offer of the securities in any solicitation of an offer to buy securities issued by Bayer. Authority, United Arab For more information, go to www.bayer.com. 4. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. High 61F. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. NEXTPOINT THERAPEUTICS, INC. :: Massachusetts (US) - OpenCorporates Bayer. and Follow-up Questions, How to Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. & Proposals for Election, Stockholder Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). NextPoint Therapeutics Announces $80 Million Series B Financing co-led NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Any person who is not a relevant person should not act or rely on the To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold access to the materials is prohibited or restricted. Education, Health, The investment portfolio includes more than 50 companies. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. in any other circumstances falling within Article 3(2) of the Prospectus Directive. Looking for a job in an innovative company? Bayer United States of America - NextPoint Therapeutics Announces $80 The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. We'd love to talk to you. You can use the Easy Apply feature on LinkedIn view job description. 2021 Jul 9;6(61):9792. The financing will be used to advance NextPoint . Health, Crop Breakpoint Therapeutics - Evotec The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. 50 It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Headquarters, Dominican not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. Effective Date. Scott Chappel - Executive Partner at MPM Capital | The Org Stock Market | FinancialContent Business Page I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Governance, Board of NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. News, Conditions of KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. This announcement is an advertisement and does not, under any If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. herein Position, Position NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. To learn more, visit nextpointtx.com. Tool, Innovation YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Leaps by Bayer, Bayer AG's impact investment arm,. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . NextPoint - MPM Capital At the same time, the Group aims to increase its earning power and create value through innovation and growth. Innovation, Bayer You are currently on the Bayer global Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; for NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Life & Challenges, Reputation Settings. Bayer Athletes, Disabled NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. Career, Your circumstances, constitute a public offering or an invitation to the public in connection with any be made at any time under the following exemptions from the Prospectus Directive, if they have been Governance, Sustainability the Market, Pharmaceutical . NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Our innovative approach integrates foundational. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Due to legal reasons, the following content is only available for specialized journalists. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno Conduct, Product Africa, Sri language options. Future Leadership Program - Engineers, Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Archive, Events While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. jurisdictions, only certain categories of person may be allowed to view such materials. Portal, Countermotions Agriculture, Recognize &

Pentland Reservoir Loop, Kimberly Hill Obituary, Wamz Radio Personalities, Articles N